Financière de Tubize S.A.
TUB
Classifica tra le azioni
#2179
Financière de Tubize SA, headquartered in Brussels, Belgium, operates as a... Financière de Tubize SA, headquartered in Brussels, Belgium, operates as a global biopharmaceutical firm, primarily through its investment in UCB. The company is dedicated to discovering and advancing innovative medicines and solutions focused on neurological and immunological disorders. Its current commercial offerings include Cimzia, an established treatment for a range of inflammatory conditions such as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis. For partial-onset seizures in epilepsy, it provides Briviact, Vimpat, and Keppra, alongside Nayzilam, a nasal spray. Neupro addresses Parkinson's disease and restless legs syndrome. Additionally, the portfolio features Evenity, an injectable therapy for osteoporosis, and Bimzelx, used to manage moderate to severe plaque psoriasis. The company's development pipeline highlights several promising candidates: Staccato, aimed at stereotypical prolonged seizures; Bepranemab for Alzheimer's disease; and UCB0599 for Parkinson's disease. Other therapies under investigation include bimekizumab, which targets psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab, for conditions like myasthenia gravis, immune thrombocytopenia, myelin oligodendrocyte glycoprotein antibody disease, and autoimmune encephalitis; and dapirolizumab pegol, intended for systemic lupus erythematosus.
Prezzo delle azioni
$209.59
Capitalizzazione di mercato
$9.33B
Variazione (1 giorno)
1.55%
Variazione (1 anno)
-23.56%
Paese
BE
Scambia Financière de Tubize S.A. (TUB)
Categoria
Healthcare
EPS per Financière de Tubize S.A. (TUB)
EPS al June 2026 TTM: $2.62
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Financière de Tubize S.A., l’EPS attuale della società (TTM) è $2.62. Alla fine del 2023, la società aveva un EPS di $2.19 un aumento rispetto a rispetto a quello del 2022, che era di $2.05.
Storico EPS per Financière de Tubize S.A. da 2003 a 2026
EPS alla fine di ogni anno
| Anno | EPS | Cambia |
|---|---|---|
| 2026 (TTM) | $2.62 | 24.83% |
| 2024 | $2.10 | -3.97% |
| 2023 | $2.19 | 6.83% |
| 2022 | $2.05 | -4.16% |
| 2021 | $2.14 | -69.99% |
| 2020 | $7.12 | -25,913.77% |
| 2019 | $-0.03 | -100.37% |
| 2018 | $7.37 | -4.38% |
| 2017 | $7.70 | 79.89% |
| 2016 | $4.28 | -17.32% |
| 2015 | $5.18 | 214.76% |
| 2014 | $1.65 | -13.29% |
| 2013 | $1.90 | -17.32% |
| 2012 | $2.30 | 22.27% |
| 2011 | $1.88 | 198.71% |
| 2010 | $0.63 | -88.03% |
| 2009 | $5.25 | -18,644.17% |
| 2008 | $-0.03 | -102.18% |
| 2007 | $1.30 | -90.76% |
| 2006 | $14.08 | 80.81% |
| 2005 | $7.79 | 111.12% |
| 2004 | $3.69 | -20.63% |
| 2003 | $4.65 | 0.00% |
EPS per aziende simili o concorrenti
| Azienda | EPS | Differenza di EPS | Il paese |
|---|---|---|---|
| $17.32 | 560.72% |
US
|
|
| $-7.98 | -404.42% |
US
|
|
| $-5.29 | -301.80% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | 958.21% |
NL
|
